Obgemsa (vibegron)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- vibegron
- Company
- Pierre Fabre Medicament
- Status
- Authorised
- Therapeutic area
- Urinary Bladder, Overactive; Urinary Incontinence
- CHMP opinion
- Thu 25 Apr 2024
- EU approval
- Thu 27 Jun 2024
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005957
- ATC
- G04BD15
- Official record
- www.ema.europa.eu
Indication
Obgemsa is indicated in symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.
Regulatory milestones
No milestones recorded in the last year.
Follow Obgemsa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.